BindingDB logo
myBDB logout

48 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
26190460 2 Chemical synthesis of tetracyclic terpenes and evaluation of antagonistic activity on endothelin-A receptors and voltage-gated calcium channels.EBI Kansas State University
25614116 13 Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity.EBI Southeast University
11809055 1 New chlorinated diphenyl ethers from an Aspergillus species.EBI University of Western Australia
15055997 42 Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.EBI Encysive Pharmaceuticals Inc.
11585442 20 Potent and selective ET-A antagonists. 2. Discovery and evaluation of potent and water soluble N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives.EBI Tanabe Seiyaku Co., Ltd.
9857090 158 Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
9667964 38 Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives.EBI Rh£ne-Poulenc Rorer
9216842 28 Design of a potent combined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DBhg16-Leu-Asp-Ile-[NMe]Ile-Trp21 (PD 156252): examination of its pharmacokinetic and spectral properties.EBI Warner-Lambert Company
8410970 106 Structure-activity relationships of C-terminal endothelin hexapeptide antagonists.EBI Warner-Lambert Company
1315867 31 Endothelin: a new challenge.EBI Warner-Lambert Company
1324321 20 Design of a functional hexapeptide antagonist of endothelin.EBI Warner-Lambert Company
9873432 52 Endothelin antagonists: discovery of EMD 122946, a highly potent and orally active ETA selective antagonist.EBI Merck KGaA
 28 Structure-activity and biophysical studies of the C-terminal hexapeptide of endothelinEBI TBA
 21 Design and synthesis of nonpeptidal endothelin receptor antagonists based on the structure of a cyclic pentapeptideEBI TBA
 23 Structure-activity relationships of monocyclic endothelin analogsEBI TBA
 10 A Novel Class of Non-Peptidic Endothelin Antagonists Isolated from the Medicinal Herb Phyllanthus niruriEBI TBA
 56 Pyridazinones with a pendant acylsulfonamide moiety as endothelin receptor antagonistsEBI TBA
 26 1,4-Diaryl-2-oxo-1,2-dihydro-quinoline-3-carboxylic acids as endothelin receptor antagonistsEBI TBA
 32 Quantitative structure-activity relationships study of endothelin-1 analogsEBI TBA
 25 Structure-activity relationships in a series of monocyclic endothelin analoguesEBI TBA
 28 Design of C-terminal peptide antagonists of endothelin: structure-activity relationships of ET-[16–21, D-His16]EBI TBA
 5 CGS 27830, a potent nonpeptide endothelin receptor antagonistEBI TBA
15139753 55 Chemical function based pharmacophore generation of endothelin-A selective receptor antagonists.EBI University of Innsbruck
11985472 185 Structure-activity relationships of a novel class of endothelin-A receptor antagonists and discovery of potent and selective receptor antagonist, 2-(benzo[1,3]dioxol-5-yl)-6-isopropyloxy-4-(4-methoxyphenyl)-2H-chromene-3-carboxylic acid (S-1255). 1. Study on structure-activity relationships and basEBI Shionogi & Co., Ltd.
11738578 26 Modifications and structure-activity relationships at the 2-position of 4-sulfonamidopyrimidine derivatives as potent endothelin antagonists.EBI Tanabe Seiyaku Co. Ltd.
11689084 47 Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonists.EBI Abbott Laboratories
11585441 70 Potent and selective ET-A antagonists. 1. Syntheses and structure-activity relationships of N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives.EBI Tanabe Seiyaku Co., Ltd.
11086733 56 Potent nonpeptide endothelin antagonists: synthesis and structure-activity relationships of pyrazole-5-carboxylic acids.EBI Hoechst Marion Roussel
10969989 45 Discovery and synthesis of a potent sulfonamide ET(B) selective antagonist.EBI Shionogi & Co., Ltd.
10890162 52 Nonpeptide endothelin antagonists: from lower affinity pyrazol-5-ols to higher affinity pyrazole-5-carboxylic acids.EBI Hoechst Marion Roussel
10715156 35 Selective ET(A) antagonists. 5. Discovery and structure-activity relationships of phenoxyphenylacetic acid derivatives.EBI Rhône-Poulenc Rorer
10098676 52 Benzofuro[3,2-b]pyridines as mixed ET(A)/ET(B) and selective ET(B) endothelin receptor antagonists.EBI Merck KGaA
9871621 26 Endothelin antagonists: evaluation of 2,1,3-benzothiadiazole as a methylendioxyphenyl bioisoster.EBI Merck KGaA
9703472 112 Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).EBI Abbott Laboratories
9667965 29 Selective endothelin A receptor antagonists. 4. Discovery and structure-activity relationships of stilbene acid and alcohol derivatives.EBI Rhône-Poulenc Rorer
9379441 100 Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.EBI Abbott Laboratories
9022798 58 Potent and selective non-benzodioxole-containing endothelin-A receptor antagonists.EBI Abbott Laboratories
8676339 143 2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.EBI Abbott Laboratories
8632420 112 Azole endothelin antagonists. 2. Structure-activity studies.EBI Abbott Laboratories
8632419 50 Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profile.EBI Abbott Laboratories
8308857 19 The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
7861414 36 Three-dimensional quantitative structure-activity relationships of sulfonamide endothelin inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
7731020 87 Discovery and structure-activity relationships of sulfonamide ETA-selective antagonists.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
7731010 56 Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists.EBI Warner-Lambert Company
7636842 155 Structure-activity relationships of the potent combined endothelin-A/endothelin-B receptor antagonist Ac-DDip16-Leu-Asp-Ile-Ile-Trp21: development of endothelin-B receptor selective antagonists.EBI Warner-Lambert Company
12721338 61 N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.BDB Pudue Pharma Discovery Research
11082453 77 ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse.BDB Abbott Laboratories